These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38623719)

  • 1. 2023 Australian guideline for assessing and managing cardiovascular disease risk.
    Nelson MR; Banks E; Brown A; Chow CK; Peiris DP; Stocks NP; Davies Ao R; Raffoul N; Kalman L; Bradburn E; Jennings G
    Med J Aust; 2024 May; 220(9):482-490. PubMed ID: 38623719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary prevention of cardiovascular disease: new guidelines, technologies and therapies.
    Nelson MR; Doust JA
    Med J Aust; 2013 Jun; 198(11):606-10. PubMed ID: 23919708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing, communicating and managing cardiovascular disease risk: a practical summary of the 2023 guideline.
    Jennings G; Raffoul N; Nelson M; Australian Guideline For Assessing And Managing Cardiovascular Disease Risk ESGFT
    Aust Prescr; 2024 Apr; 47(2):57-63. PubMed ID: 38737366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular disease risk assessment for Aboriginal and Torres Strait Islander adults aged under 35 years: a consensus statement.
    Agostino JW; Wong D; Paige E; Wade V; Connell C; Davey ME; Peiris DP; Fitzsimmons D; Burgess CP; Mahoney R; Lonsdale E; Fernando P; Malamoo L; Eades S; Brown A; Jennings G; Lovett RW; Banks E
    Med J Aust; 2020 May; 212(9):422-427. PubMed ID: 32172533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of three different methods of assessing cardiovascular disease risk in New Zealanders with Type 2 diabetes mellitus.
    Metcalf PA; Wells S; Scragg RK; Jackson R
    N Z Med J; 2008 Sep; 121(1281):49-57. PubMed ID: 18797484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How do the Australian guidelines for lipid-lowering drugs perform in practice? Cardiovascular disease risk in the AusDiab Study, 1999-2000.
    Chen L; Rogers SL; Colagiuri S; Cadilhac DA; Mathew TH; Boyden AN; Peeters A; Magliano DJ; Shaw JE; Zimmet PZ; Tonkin AM;
    Med J Aust; 2008 Sep; 189(6):319-22. PubMed ID: 18803535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initiation and maintenance of cardiovascular medications following cardiovascular risk assessment in a large primary care cohort: PREDICT CVD-16.
    Mehta S; Wells S; Grey C; Riddell T; Kerr A; Marshall R; Ameratunga S; Harrison J; Kenealy T; Bramley D; Chan WC; Thornley S; Sundborn G; Jackson R
    Eur J Prev Cardiol; 2014 Feb; 21(2):192-202. PubMed ID: 23033546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of New Zealand CVD risk chart adjustments for family history and ethnicity on eligibility for treatment (PREDICT CVD-5).
    Wells S; Kerr A; Broad J; Riddell T; Kenealy T; Jackson R
    N Z Med J; 2007 Sep; 120(1261):U2712. PubMed ID: 17853933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guideline-Based Statin Eligibility, Coronary Artery Calcification, and Cardiovascular Events.
    Pursnani A; Massaro JM; D'Agostino RB; O'Donnell CJ; Hoffmann U
    JAMA; 2015 Jul; 314(2):134-41. PubMed ID: 26172893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are the benefits of aspirin likely to exceed the risk of major bleeds among people in whom aspirin is recommended for the primary prevention of cardiovascular disease?
    Selak V; Jackson R; Poppe K; Kerr A; Wells S
    N Z Med J; 2018 Oct; 131(1484):19-25. PubMed ID: 30359352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absolute risk of cardiovascular disease events, and blood pressure- and lipid-lowering therapy in Australia.
    Banks E; Crouch SR; Korda RJ; Stavreski B; Page K; Thurber KA; Grenfell R
    Med J Aust; 2016 May; 204(8):320. PubMed ID: 27125809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polygenic risk scores in cardiovascular risk prediction: A cohort study and modelling analyses.
    Sun L; Pennells L; Kaptoge S; Nelson CP; Ritchie SC; Abraham G; Arnold M; Bell S; Bolton T; Burgess S; Dudbridge F; Guo Q; Sofianopoulou E; Stevens D; Thompson JR; Butterworth AS; Wood A; Danesh J; Samani NJ; Inouye M; Di Angelantonio E
    PLoS Med; 2021 Jan; 18(1):e1003498. PubMed ID: 33444330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular disease risk management for Aboriginal and Torres Strait Islander peoples in primary health care settings: findings from the Kanyini Audit.
    Peiris DP; Patel AA; Cass A; Howard MP; Tchan ML; Brady JP; De Vries J; Rickards BA; Yarnold DJ; Hayman NE; Brown AD
    Med J Aust; 2009 Sep; 191(6):304-9. PubMed ID: 19769551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. External validation and comparison of four cardiovascular risk prediction models with data from the Australian Diabetes, Obesity and Lifestyle study.
    Albarqouni L; Doust JA; Magliano D; Barr EL; Shaw JE; Glasziou PP
    Med J Aust; 2019 Mar; 210(4):161-167. PubMed ID: 30656697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time to improve statin prescription guidelines in low-risk patients?
    Balder JW; de Vries JK; Mulder DJ; Kamphuisen PW
    Eur J Prev Cardiol; 2017 Jul; 24(10):1064-1070. PubMed ID: 28429651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absolute cardiovascular disease risk score and pharmacotherapy at the time of admission in patients presenting with acute coronary syndrome due to coronary artery disease in a single Australian tertiary centre: a cross-sectional study.
    Bailey A; Korda R; Agostino J; Stanton T; Kelly G; Richman T; Greaves K
    BMJ Open; 2021 Feb; 11(2):e038868. PubMed ID: 33558345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing gaps in cholesterol treatment guidelines for primary prevention of cardiovascular disease based on available randomised clinical trial evidence: The Rotterdam Study.
    Pavlović J; Greenland P; Deckers JW; Kavousi M; Hofman A; Ikram MA; Franco OH; Leening MJ
    Eur J Prev Cardiol; 2018 Mar; 25(4):420-431. PubMed ID: 29171772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Future directions in cardiovascular disease risk prediction.
    Doust JA; Bonner C; Bell KJL
    Aust J Gen Pract; 2020 Aug; 49(8):488-494. PubMed ID: 32738856
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.